Research programme: imino sugar therapeutics - Summit

Drug Profile

Research programme: imino sugar therapeutics - Summit

Alternative Names: MNLP462a; SMT-14224; SMT-14400; SMT-C2100; VOX 14400

Latest Information Update: 24 Feb 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MNLpharma
  • Developer Summit plc; Summit Therapeutics
  • Class Imino sugars; Small molecules
  • Mechanism of Action Glucose modulators; Haemoglobin modulators; Hepatitis C virus NS3 protein modulators; Hexosaminidase C inhibitors; Immunomodulators; Immunostimulants; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease
  • No development reported Cancer; Diabetes mellitus; Hepatitis C; Viral infections

Most Recent Events

  • 20 Feb 2015 Summit Corporation is now called Summit Therapeuitcs
  • 14 Mar 2013 No development reported - Preclinical for Cancer in United Kingdom (PO)
  • 14 Mar 2013 No development reported - Preclinical for Diabetes mellitus in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top